Mark Jenson, MD
Family Medicine · Green Bay, WINPI 1598727000
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $184,348 of the $204,421 with a category attached, or 90.2%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 80.4% of it on its own, with 59 other manufacturers making up the rest. Among family medicine clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,270 payments — averaging $160.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$164K
- Shire North American Group Inc$22K
- AbbVie$2K
- Lilly USA, LLC$2K
- Amgen$1K
- AstraZeneca$1K
- plus $12K from 54 others
What the payments were for
- Consulting fees$184,34890%
- Travel & lodging$1,2431%
- Food & beverage$18,8039%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$348
- Mavyret$125
- Quillichew ER$125
- Quillivant$125
- Dyanavel XR$125
- XARELTO$118
- VRAYLAR$109
- LOKELMA$109
- Veozah$109
- AIRSUPRA$108
- BREZTRI$108
- UBRELVY$103
- FARXIGA$102
How this compares
$204,421 in reported general payments places this provider in the 95th percentile of 1,482 family medicine providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 68 | $84,875 |
| EliquisApixaban | 63 | $58,130 |
| XareltoRivaroxaban | 40 | $45,411 |
| JardianceEmpagliflozin | 53 | $44,312 |
| OzempicSemaglutide | 29 | $43,983 |
| JanumetSitagliptin Phos/Metformin Hcl | 37 | $43,445 |
| RybelsusSemaglutide | 25 | $39,156 |
| FarxigaDapagliflozin Propanediol | 32 | $36,403 |
| Amjevita(Cf) AutoinjectorAdalimumab-Atto | 11 | $34,447 |
| MounjaroTirzepatide | 18 | $33,673 |
| Nucynta ErTapentadol Hcl | 12 | $24,988 |
| MyrbetriqMirabegron | 18 | $18,874 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $17,420 |
| Repatha SureclickEvolocumab | 24 | $16,718 |
| InvokanaCanagliflozin | 12 | $15,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet, Janumet Xr | $285 | $145,741122 claims |
| Novo NordiskOzempic, Rybelsus | $1,114 | $83,13954 claims |
| Johnson & JohnsonXarelto, Invokana | $830 | $60,50052 claims |
| PfizerEliquis | $1,130 | $58,13063 claims |
| Boehringer IngelheimJardiance | $681 | $44,31253 claims |
| AstraZenecaFarxiga, Symbicort | $1,195 | $43,13046 claims |
| Lilly USA, LLCMounjaro | $1,532 | $33,67318 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $71 | $28,62839 claims |
| Collegium Pharmaceutical, Inc.Nucynta Er | $164 | $24,98812 claims |
| Astellas Pharma US IncMyrbetriq | $167 | $18,87418 claims |
| NovartisEntresto | $241 | $14,55920 claims |
| AbbVieSynthroid | $2,125 | $2,38327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,482 family medicine providers in Wisconsin.
Other family medicine in Green Bay
- Stephen HathwayGreen Bay$27K
- Lisa AllenGreen Bay$24K
- Matthew JensonGreen Bay$12K
- James WilliamsGreen Bay$8K
- Jennifer ParsleyElk Mound$1.4M
- William PalinMilwaukee$693K
- Ryan AndrewsStevens Point$429K
- Tara DallDelafield$230K
- James SamuelMount Pleasant$203K
- Daniel DuffyCedarburg$194K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.